We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+11.56%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$152M
Cap. Flow
+$78.1M
Cap. Flow %
7.15%
Top 10 Hldgs %
44.59%
Holding
100
New
19
Increased
24
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$27.9M
2
DGX icon
Quest Diagnostics
DGX
+$26.1M
3
CAH icon
Cardinal Health
CAH
+$20.8M
4
LLY icon
Eli Lilly
LLY
+$19.4M
5
CRL icon
Charles River Laboratories
CRL
+$15.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.6M
3
BPMC
Blueprint Medicines
BPMC
+$12.8M
4
KRYS icon
Krystal Biotech
KRYS
+$10.8M
5
BSX icon
Boston Scientific
BSX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$21.4B
$161M 14.74%
1,600,000
+50,000
+3% +$3.82M
BSX icon
2
Boston Scientific
BSX
$69.5B
$59.1M 5.41%
550,000
-100,000
-15% -$10.1M
THC icon
3
Tenet Healthcare
THC
$20.5B
$48.4M 4.43%
275,000
– –
EHC icon
4
Encompass Health
EHC
$11B
$39.2M 3.59%
320,000
+50,000
+19% +$5.71M
MLYS icon
5
Mineralys Therapeutics
MLYS
$2.25B
$36.5M 3.34%
2,700,000
+400,000
+17% +$5.8M
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$33M 3.02%
1,000,000
-100,000
-9% -$3.48M
BTSG icon
7
BrightSpring Health Services
BTSG
$11.7B
$29.5M 2.7%
1,250,000
+475,000
+61% +$9.91M
VERA icon
8
Vera Therapeutics
VERA
$2.3B
$27.1M 2.48%
1,150,000
– –
DGX icon
9
Quest Diagnostics
DGX
$25.7B
$26.9M 2.47%
+150,000
New +$26.1M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$78.5B
$26.3M 2.4%
+50,000
New +$27.9M
NVS icon
11
Novartis
NVS
$297B
$24.2M 2.22%
200,000
-50,000
-20% -$5.64M
CAH icon
12
Cardinal Health
CAH
$53.9B
$23.5M 2.15%
+140,000
New +$20.8M
ELV icon
13
Elevance Health
ELV
$81.5B
$23.3M 2.14%
60,000
-5,000
-8% -$2.01M
RDNT icon
14
RadNet
RDNT
$5.02B
$22.8M 2.08%
400,000
+150,000
+60% +$8.24M
FMS icon
15
Fresenius Medical Care
FMS
$13.8B
$21.4M 1.96%
750,000
+70,000
+10% +$1.88M
LLY icon
16
Eli Lilly
LLY
$1.02T
$19.5M 1.78%
+25,000
New +$19.4M
NBIX icon
17
Neurocrine Biosciences
NBIX
$16.8B
$18.9M 1.73%
150,000
– –
QURE icon
18
uniQure
QURE
$3.03B
$18.8M 1.72%
1,350,000
+100,000
+8% +$1.35M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$27.5B
$17.9M 1.64%
55,000
+5,000
+10% +$1.38M
DXCM icon
20
DexCom
DXCM
$31.5B
$17.5M 1.6%
200,000
+100,000
+100% +$7.84M
CRL icon
21
Charles River Laboratories
CRL
$11.2B
$17.4M 1.6%
+115,000
New +$15.3M
MDT icon
22
Medtronic
MDT
$109B
$17.4M 1.6%
200,000
-100,000
-33% -$8.48M
CVS icon
23
CVS Health
CVS
$133B
$17.2M 1.58%
250,000
+50,000
+25% +$3.28M
PFE icon
24
Pfizer
PFE
$143B
$17M 1.55%
700,000
+400,000
+133% +$9.33M
CYTK icon
25
CALL
Cytokinetics
CYTK
$10.5B
$16.5M 1.51%
+500,000
New +$17.4M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Integral Health Asset Management held 100 positions worth $1.09B, up 16% from $940M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $78.1M of net new capital in Q2 2025, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Boston Scientific, an estimated $10.1M trimmed.

  • Integral Health Asset Management's largest Q2 2025 buy was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.
  • Integral Health Asset Management added most to BrightSpring Health Services in Q2 2025, an estimated $9.91M increase.
  • Integral Health Asset Management's biggest Q2 2025 reduction was Boston Scientific, cutting an estimated $10.1M.
  • Integral Health Asset Management fully exited Gilead Sciences in Q2 2025, selling an estimated $19.6M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.09B portfolio in Q2 2025.
  • Integral Health Asset Management opened 19 new positions and closed 28 in Q2 2025.
  • Integral Health Asset Management's portfolio value rose 16% quarter-over-quarter to $1.09B.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.